本研究旨在評估relatlimab聯合nivolumab在曾接受酪氨酸激酶抑制劑治療後、從未接受免疫腫瘤治療的晚期肝癌參與者中的療效及安全性。
適應症：Hepatocellular Carcinoma、Hepatoma、Liver Cancer, Adult、Liver Cell Carcinoma、Liver Cell Carcinoma, Adult
收案條件
納入條件
- Must have a diagnosis of hepatocellular carcinoma (HCC) based on histological confirmation
- Must have advanced/metastatic HCC
- Have to be immunotherapy treatment-naive in the advanced/metastatic setting
- Must have at least one Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 measurable untreated lesion
- Child-Pugh score of 5 or 6
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 for ECOG performance status scale
排除條件
- Known fibrolamellar HCC, sarcomatoid HCC, combined hepatocellular cholangiocarcinoma
- Prior organ allograft or allogeneic bone marrow transplantation
- No uncontrolled or significant cardiovascular disease
- No active known autoimmune disease
- Have received one or two lines of tyrosine kinase inhibitor therapies
- Evidence of radiographic progression on or after the last line of tyrosine kinase inhibitor therapy
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。